A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies

Bibliography

• Cleveland DW. From Charcot to SOD1: mechanisms of selective motor neuron death in ALS. Neuron 1999;24(3):515-20
   PubMed Web of Science ®Google Scholar
• Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001;2(11):806-19
   PubMed Web of Science ®Google Scholar
• Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 2009;65(Suppl 1):S3-9
   PubMed Web of Science ®Google Scholar
• Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;364(6435):362
   PubMed Web of Science ®Google Scholar
• DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72(2):245-56
   PubMed Web of Science ®Google Scholar
• Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72(2):257-68
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330(9):585-91
   PubMed Web of Science ®Google Scholar
• Jablonski MR, Markandaiah SS, Jacob D, et al. Inhibiting drug efflux transporters improves efficacy of ALS therapeutics. Ann Clin Transl Neurol 2014;1(12):996-1005
   Google Scholar
• Cudkowicz ME, Katz J, Moore DH, et al. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010;11(3):259-65
   PubMed Web of Science ®Google Scholar
• Turner MR, Benatar M. Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis. Muscle Nerve 2015;51(1):14-18
   PubMed Web of Science ®Google Scholar
• Bakkar N, Boehringer A, Bowser R. Use of biomarkers in ALS drug development and clinical trials. Brain Res 2015;1607:94-107
   PubMed Web of Science ®Google Scholar
• Lu CH, Macdonald-Wallis C, Gray E, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology 2015;84(22):2247-57
   PubMed Web of Science ®Google Scholar
• Berry JD, Cudkowicz ME. New considerations in the design of clinical trials for amyotrophic lateral sclerosis. Clin Investig (Lond) 2011;1(10):1375-89
   Google Scholar
• Bruijn L, Cudkowicz M. Opportunities for improving therapy development in ALS. Amyotroph Lateral Scler Frontotemporal Degener 2014;15(3-4):169-73
   PubMed Web of Science ®Google Scholar
• Nicholson KA, Cudkowicz ME, Berry JD. Clinical trial designs in amyotrophic lateral sclerosis: Does one design fit all? Neurotherapeutics 2015;12(2):376-83
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol 2014;13(11):1127-38
   PubMed Web of Science ®Google Scholar
• Kiaei M, Kipiani K, Chen J, et al. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 2005;191(2):331-6
   PubMed Web of Science ®Google Scholar
• Dupuis L, Dengler R, Heneka MT, et al. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS ONE 2012;7(6):e37885
   PubMed Web of Science ®Google Scholar
• Kiaei M, Kipiani K, Petri S, et al. Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neurodegener Dis 2005;2(5):246-54
   PubMed Web of Science ®Google Scholar
• Petri S, Calingasan NY, Alsaied OA, et al. The lipophilic metal chelators DP-109 and DP-460 are neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 2007;102(3):991-1000
   PubMed Web of Science ®Google Scholar
• Wu AS, Kiaei M, Aguirre N, et al. Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. J Neurochem 2003;85(1):142-50
   PubMed Web of Science ®Google Scholar
• Kiaei M, Petri S, Kipiani K, et al. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2006;26(9):2467-73
   PubMed Web of Science ®Google Scholar
• Stommel EW, Cohen JA, Fadul CE, et al. Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotroph Lateral Scler 2009;10(5-6):393-404
   PubMed Web of Science ®Google Scholar
• Neymotin A, Petri S, Calingasan NY, et al. Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 2009;220(1):191-7
   PubMed Web of Science ®Google Scholar
• Koh SH, Lee SM, Kim HY, et al. The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice. Neurosci Lett 2006;395(2):103-7
   PubMed Web of Science ®Google Scholar
• O’Connell RM, Kahn D, Gibson WS, et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 2010;33(4):607-19
   PubMed Web of Science ®Google Scholar
• Lu LF, Thai TH, Calado DP, et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 2009;30(1):80-91
   PubMed Web of Science ®Google Scholar
• Butovsky O, Jedrychowski MP, Cialic R, et al. Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann Neurol 2015;77(1):75-99
   PubMed Web of Science ®Google Scholar
• Koval ED, Shaner C, Zhang P, et al. Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice. Hum Mol Genet 2013;22(20):4127-35
   PubMed Web of Science ®Google Scholar
• Klivenyi P, Kiaei M, Gardian G, et al. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 2004;88(3):576-82
   PubMed Web of Science ®Google Scholar
• Gordon PH, Cheung YK, Levin B, et al. A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler 2008;9(4):212-22
   PubMed Web of Science ®Google Scholar
• Jablonski MR, Jacob DA, Campos C, et al. Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS. Neurobiol Dis 2012;47(2):194-200
   PubMed Web of Science ®Google Scholar
• Jablonski M, Miller DS, Pasinelli P, et al. ABC transporter-driven pharmacoresistance in Amyotrophic Lateral Sclerosis. Brain Res 2015;1607:1-14
   PubMed Web of Science ®Google Scholar
• Aggarwal SP, Zinman L, Simpson E, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9(5):481-8
   PubMed Web of Science ®Google Scholar
• Kong Q, Carothers S, Chang Y, et al. The importance of preclinical trial timing - a potential reason for the disconnect between mouse studies and human clinical trials in ALS. CNS Neurosci Ther 2012;18(9):791-3
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Patel S, Regan MR, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005;433(7021):73-7
   PubMed Web of Science ®Google Scholar
• Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 2005;58(4):495-505
   PubMed Web of Science ®Google Scholar
• Hervias I, Beal MF, Manfredi G. Mitochondrial dysfunction and amyotrophic lateral sclerosis. Muscle Nerve 2006;33(5):598-608
   PubMed Web of Science ®Google Scholar
• Beal MF. Mitochondria and neurodegeneration. Novartis Found Symp 2007;287:183-92
   PubMedGoogle Scholar
• Gribkoff VK, Bozik ME. KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis. CNS Neurosci Ther 2008;14(3):215-26
   PubMed Web of Science ®Google Scholar
• Bozik ME, Mather JL, Kramer WG, et al. Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects. J Clin Pharmacol 2011;51(8):1177-85
   PubMed Web of Science ®Google Scholar
• Cudkowicz M, Bozik ME, Ingersoll EW, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med 2011;17(12):1652-6
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, van den Berg LH, Shefner JM, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol 2013;12(11):1059-67
   PubMed Web of Science ®Google Scholar
• Vieira FG, LaDow E, Moreno A, et al. Dexpramipexole is ineffective in two models of ALS related neurodegeneration. PLoS One 2014;9(12):e91608
   PubMed Web of Science ®Google Scholar
• Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 2013;12(5):435-42
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Titus S, Kearney M, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014;13(11):1083-91
   PubMed Web of Science ®Google Scholar
• Kalmar B, Lu CH, Greensmith L. The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol. Pharmacol Ther 2014;141(1):40-54
   PubMed Web of Science ®Google Scholar
• Yanez M, Matias-Guiu J, Arranz-Tagarro JA, et al. The neuroprotection exerted by memantine, minocycline and lithium, against neurotoxicity of CSF from patients with amyotrophic lateral sclerosis, is antagonized by riluzole. Neurodegener Dis 2014;13(2-3):171-9
   PubMed Web of Science ®Google Scholar
• Vincenti MP, Brinckerhoff CE. Signal transduction and cell-type specific regulation of matrix metalloproteinase gene expression: can MMPs be good for you? J Cell Physiol 2007;213(2):355-64
   PubMed Web of Science ®Google Scholar
• Schoser BG, Blottner D. Matrix metalloproteinases MMP-2, MMP-7 and MMP-9 in denervated human muscle. Neuroreport 1999;10(13):2795-7
   PubMed Web of Science ®Google Scholar
• Lorenzl S, Narr S, Angele B, et al. The matrix metalloproteinases inhibitor Ro 28-2653 [correction of Ro 26-2853] extends survival in transgenic ALS mice. Exp Neurol 2006;200(1):166-71
   PubMed Web of Science ®Google Scholar
• Kiaei M, Kipiani K, Calingasan NY, et al. Matrix metalloproteinase-9 regulates TNF-alpha and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 2007;205(1):74-81
   PubMed Web of Science ®Google Scholar
• Kaplan A, Spiller KJ, Towne C, et al. Neuronal matrix metalloproteinase-9 is a determinant of selective neurodegeneration. Neuron 2014;81(2):333-48
   PubMed Web of Science ®Google Scholar
• Dewil M, Schurmans C, Starckx S, et al. Role of matrix metalloproteinase-9 in a mouse model for amyotrophic lateral sclerosis. Neuroreport 2005;16(4):321-4
   PubMed Web of Science ®Google Scholar
• Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD, et al. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci USA 2004;101(7):2040-5
   PubMed Web of Science ®Google Scholar
• Narasimhan M, Mahimainathan L, Rathinam ML, et al. Overexpression of Nrf2 protects cerebral cortical neurons from ethanol-induced apoptotic death. Mol Pharmacol 2011;80(6):988-99
   PubMed Web of Science ®Google Scholar
• Neymotin A, Calingasan NY, Wille E, et al. Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic Biol Med 2011;51(1):88-96
   PubMed Web of Science ®Google Scholar
• Satoh T, Rezaie T, Seki M, et al. Dual neuroprotective pathways of a pro-electrophilic compound via HSF-1-activated heat-shock proteins and Nrf2-activated phase 2 antioxidant response enzymes. J Neurochem 2011;119(3):569-78
   PubMed Web of Science ®Google Scholar
• Slocum SL, Kensler TW. Nrf2: control of sensitivity to carcinogens. Arch Toxicol 2011;85(4):273-84
   PubMed Web of Science ®Google Scholar
• Sarlette A, Krampfl K, Grothe C, et al. Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2008;67(11):1055-62
   PubMed Web of Science ®Google Scholar
• Kirby J, Halligan E, Baptista MJ, et al. Mutant SOD1 alters the motor neuronal transcriptome: implications for familial ALS. Brain 2005;128(Pt 7):1686-706
   PubMed Web of Science ®Google Scholar
• Dumont M, Wille E, Calingasan NY, et al. Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer’s disease. J Neurochem 2009;109(2):502-12
   PubMed Web of Science ®Google Scholar
• Yang L, Calingasan NY, Thomas B, et al. Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS One 2009;4(6):e5757
   PubMed Web of Science ®Google Scholar
• Stack C, Ho D, Wille E, et al. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington’s disease. Free Radic Biol Med 2010;49(2):147-58
   PubMed Web of Science ®Google Scholar
• Suh JH, Shenvi SV, Dixon BM, et al. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci U S A 2004;101(10):3381-6
   PubMed Web of Science ®Google Scholar
• Calkins MJ, Jakel RJ, Johnson DA, et al. Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. Proc Natl Acad Sci U S A 2005;102(1):244-9
   PubMed Web of Science ®Google Scholar
• Kwak MK, Itoh K, Yamamoto M, et al. Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: role of antioxidant response element-like sequences in the nrf2 promoter. Mol Cell Biol 2002;22(9):2883-92
   PubMed Web of Science ®Google Scholar
• van Muiswinkel FL, Kuiperij HB. The Nrf2-ARE Signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders. Curr Drug Targets CNS Neurol Disord 2005;4(3):267-81
   PubMedGoogle Scholar
• Graber DJ, Park PJ, Hickey WF, et al. Synthetic triterpenoid CDDO derivatives modulate cytoprotective or immunological properties in astrocytes, neurons, and microglia. J Neuroimmune Pharmacol 2011;6(1):107-20
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314(5796):130-3
   PubMed Web of Science ®Google Scholar
• Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006;351(3):602-11
   PubMed Web of Science ®Google Scholar
• Baird L, Dinkova-Kostova AT. The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol 2011;85(4):241-72
   PubMed Web of Science ®Google Scholar
• Borchelt DR, Lee MK, Slunt HS, et al. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc Natl Acad Sci U S A 1994;91(17):8292-6
   PubMed Web of Science ®Google Scholar
• Gitcho MA, Baloh RH, Chakraverty S, et al. TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol 2008;63(4):535-8
   PubMed Web of Science ®Google Scholar
• Hand CK, Mayeux-Portas V, Khoris J, et al. Compound heterozygous D90A and D96N SOD1 mutations in a recessive amyotrophic lateral sclerosis family. Ann Neurol 2001;49(2):267-71
   PubMed Web of Science ®Google Scholar
• Kwiatkowski TJJr, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009;323(5918):1205-8
   PubMed Web of Science ®Google Scholar
• Vance C, Rogelj B, Hortobagyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009;323(5918):1208-11
   PubMed Web of Science ®Google Scholar
• Morita M, Al-Chalabi A, Andersen PM, et al. A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology 2006;66(6):839-44
   PubMed Web of Science ®Google Scholar
• Vance C, Al-Chalabi A, Ruddy D, et al. Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Brain 2006;129(Pt 4):868-76
   PubMed Web of Science ®Google Scholar
• Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012;11(4):323-30
   PubMed Web of Science ®Google Scholar
• Fratta P, Polke JM, Newcombe J, et al. Screening a UK amyotrophic lateral sclerosis cohort provides evidence of multiple origins of the C9orf72 expansion. Neurobiol Aging 2015;36(1):546e541-7
   Web of Science ®Google Scholar
• Komatsu M. Liver autophagy: physiology and pathology. J Biochem 2012;152(1):5-15
   PubMed Web of Science ®Google Scholar
• Chew J, Gendron TF, Prudencio M, et al. Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science 2015;348(6239):1151-4
   PubMed Web of Science ®Google Scholar
• Xi Z, Rainero I, Rubino E, et al. Hypermethylation of the CpG-island near the C9orf72 G(4)C(2)-repeat expansion in FTLD patients. Hum Mol Genet 2014;23(21):5630-7
   PubMed Web of Science ®Google Scholar
• Xi Z, Zhang M, Bruni AC, et al. The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients. Acta Neuropathol 2015;129(5):715-27
   PubMed Web of Science ®Google Scholar
• Fratta P, Poulter M, Lashley T, et al. Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. Acta Neuropathol 2013;126(3):401-9
   PubMed Web of Science ®Google Scholar
• Almeida S, Gascon E, Tran H, et al. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol 2013;126(3):385-99
   PubMed Web of Science ®Google Scholar
• Gijselinck I, Van Langenhove T, van der Zee J, et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol 2012;11(1):54-65
   PubMed Web of Science ®Google Scholar
• Belzil VV, Bauer PO, Prudencio M, et al. Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathol 2013;126(6):895-905
   PubMed Web of Science ®Google Scholar
• Orr HT. Toxic RNA as a driver of disease in a common form of ALS and dementia. P Natl Acad Sci USA 2013;110(19):7533-4
   PubMed Web of Science ®Google Scholar
• Cooper TA, Wan L, Dreyfuss G. RNA and disease. Cell 2009;136(4):777-93
   PubMed Web of Science ®Google Scholar
• Gendron TF, Bieniek KF, Zhang YJ, et al. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol 2013;126(6):829-44
   PubMed Web of Science ®Google Scholar
• Zu T, Liu Y, Banez-Coronel M, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A 2013;110(51):E4968-77
   PubMed Web of Science ®Google Scholar
• Ash PE, Bieniek KF, Gendron TF, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 2013;77(4):639-46
   PubMed Web of Science ®Google Scholar
• Mori K, Weng SM, Arzberger T, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 2013;339(6125):1335-8
   PubMed Web of Science ®Google Scholar
• Mori K, Arzberger T, Grasser FA, et al. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol 2013;126(6):881-93
   PubMed Web of Science ®Google Scholar
• Zu T, Gibbens B, Doty NS, et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci U S A 2011;108(1):260-5
   PubMed Web of Science ®Google Scholar
• Cleary JD, Ranum LP. Repeat-associated non-ATG (RAN) translation in neurological disease. Hum Mol Genet 2013;22(R1):R45-51
   PubMed Web of Science ®Google Scholar
• Hagerman RJ, Leehey M, Heinrichs W, et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001;57(1):127-30
   PubMed Web of Science ®Google Scholar
• Donnelly CJ, Zhang PW, Pham JT, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 2013;80(2):415-28
   PubMed Web of Science ®Google Scholar
• Lagier-Tourenne C, Baughn M, Rigo F, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A 2013;110(47):E4530-9
   PubMed Web of Science ®Google Scholar
• Sareen D, O’Rourke JG, Meera P, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med 2013;5(208):208ra149
   PubMed Web of Science ®Google Scholar
• Zamiri B, Reddy K, Macgregor RBJr, et al. TMPyP4 porphyrin distorts RNA G-quadruplex structures of the disease-associated r(GGGGCC)n repeat of the C9orf72 gene and blocks interaction of RNA-binding proteins. J Biol Chem 2014;89(8):4653-9
   Web of Science ®Google Scholar
• Cirulli ET, Lasseigne BN, Petrovski S, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 2015;347(6229):1436-41
   PubMed Web of Science ®Google Scholar
• Kachaner D, Genin P, Laplantine E, et al. Toward an integrative view of Optineurin functions. Cell Cycle 2012;11(15):2808-18
   PubMed Web of Science ®Google Scholar
• Ramaswami M, Taylor JP, Parker R. Altered ribostasis: RNA-protein granules in degenerative disorders. Cell 2013;154(4):727-36
   PubMed Web of Science ®Google Scholar
• Glass CK, Saijo K, Winner B, et al. Mechanisms underlying inflammation in neurodegeneration. Cell 2010;140(6):918-34
   PubMed Web of Science ®Google Scholar
• Freischmidt A, Wieland T, Richter B, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci 2015;18(5):631-6
   PubMed Web of Science ®Google Scholar
• Meamar R, Nasr-Esfahani MH, Mousavi SA, et al. Stem cell therapy in amyotrophic lateral sclerosis. J Clin Neurosci 2013;20(12):1659-63
   PubMed Web of Science ®Google Scholar
• Thomsen GM, Gowing G, Svendsen S, et al. The past, present and future of stem cell clinical trials for ALS. Exp Neurol 2014;262(Pt B):127-37
   PubMed Web of Science ®Google Scholar
• Svendsen CN. Back to the future: how human induced pluripotent stem cells will transform regenerative medicine. Hum Mol Genet 2013;22(R1):R32-8
   PubMed Web of Science ®Google Scholar
• Bellin M, Marchetto MC, Gage FH, et al. Induced pluripotent stem cells: the new patient? Nat Rev Mol Cell Biol 2012;13(11):713-26
   PubMed Web of Science ®Google Scholar
• Sandoe J, Eggan K. Opportunities and challenges of pluripotent stem cell neurodegenerative disease models. Nat Neurosci 2013;16(7):780-9
   PubMed Web of Science ®Google Scholar
• Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008;321(5893):1218-21
   PubMed Web of Science ®Google Scholar
• Lunn JS, Sakowski SA, Federici T, et al. Stem cell technology for the study and treatment of motor neuron diseases. Regen Med 2011;6(2):201-13
   PubMed Web of Science ®Google Scholar
• Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010;67(10):1187-94
   PubMed Web of Science ®Google Scholar
• Xu L, Yan J, Chen D, et al. Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats. Transplantation 2006;82(7):865-75
   PubMed Web of Science ®Google Scholar
• Yan J, Xu L, Welsh AM, et al. Combined immunosuppressive agents or CD4 antibodies prolong survival of human neural stem cell grafts and improve disease outcomes in amyotrophic lateral sclerosis transgenic mice. Stem Cells 2006;24(8):1976-85
   PubMed Web of Science ®Google Scholar
• Knippenberg S, Rath KJ, Boselt S, et al. Intraspinal administration of human spinal cord-derived neural progenitor cells in the G93A-SOD1 mouse model of ALS delays symptom progression, prolongs survival and increases expression of endogenous neurotrophic factors. J Tissue Eng Regen Med 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Wu CH, Fallini C, Ticozzi N, et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature 2012;488(7412):499-503
   PubMed Web of Science ®Google Scholar
• Ingre C, Landers JE, Rizik N, et al. A novel phosphorylation site mutation in profilin 1 revealed in a large screen of US, Nordic, and German amyotrophic lateral sclerosis/frontotemporal dementia cohorts. Neurobiol Aging 2013;34(6):1708e1-6
   Web of Science ®Google Scholar
• Smith BN, Ticozzi N, Fallini C, et al. Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. Neuron 2014;84(2):324-31
   PubMed Web of Science ®Google Scholar
• Daoud H, Dobrzeniecka S, Camu W, et al. Mutation analysis of PFN1 in familial amyotrophic lateral sclerosis patients. Neurobiol Aging 2013;34(4):1311e1-2
   Web of Science ®Google Scholar
• Lattante S, Le Ber I, Camuzat A, et al. Mutations in the PFN1 gene are not a common cause in patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration in France. Neurobiol Aging 2013;34(6):1709e1-2
   Web of Science ®Google Scholar
• Tiloca C, Ticozzi N, Pensato V, et al. Screening of the PFN1 gene in sporadic amyotrophic lateral sclerosis and in frontotemporal dementia. Neurobiol Aging 2013;34(5):1517e9-10
   Web of Science ®Google Scholar
• Al-Chalabi A, Andersen PM, Nilsson P, et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet 1999;8(2):157-64
   PubMed Web of Science ®Google Scholar
• Gros-Louis F, Lariviere R, Gowing G, et al. A frameshift deletion in peripherin gene associated with amyotrophic lateral sclerosis. J Biol Chem 2004;279(44):45951-6
   PubMed Web of Science ®Google Scholar
• Puls I, Jonnakuty C, LaMonte BH, et al. Mutant dynactin in motor neuron disease. Nat Genet 2003;33(4):455-6
   PubMed Web of Science ®Google Scholar
• Rademakers R, van Blitterswijk M. Excess of Rare Damaging TUBA4A Variants Suggests Cytoskeletal Defects in ALS. Neuron 2014;84(2):241-3
   PubMed Web of Science ®Google Scholar
• Witke W, Podtelejnikov AV, Di Nardo A, et al. In mouse brain profilin I and profilin II associate with regulators of the endocytic pathway and actin assembly. Embo J 1998;17(4):967-76
   PubMed Web of Science ®Google Scholar
• Mockrin SC, Korn ED. Acanthamoeba profilin interacts with G-actin to increase the rate of exchange of actin-bound adenosine 5’-triphosphate. Biochemistry 1980;19(23):5359-62
   PubMed Web of Science ®Google Scholar
• Tilney LG, Bonder EM, Coluccio LM, et al. Actin from Thyone sperm assembles on only one end of an actin filament: a behavior regulated by profilin. J Cell Biol 1983;97(1):112-24
   PubMed Web of Science ®Google Scholar
• Witke W. The role of profilin complexes in cell motility and other cellular processes. Trends Cell Biol 2004;14(8):461-9
   PubMed Web of Science ®Google Scholar
• Rustici G, Kolesnikov N, Brandizi M, et al. ArrayExpress update–trends in database growth and links to data analysis tools. Nucleic Acids Res 2013;41:D987-90
   PubMed Web of Science ®Google Scholar
• Van Hoecke A, Schoonaert L, Lemmens R, et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med 2012;18(9):1418-22
   PubMed Web of Science ®Google Scholar
• Pasquale EB. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 2005;6(6):462-75
   PubMed Web of Science ®Google Scholar
• Landers JE, Melki J, Meininger V, et al. Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2009;106(22):9004-9
   PubMed Web of Science ®Google Scholar
• van Doormaal PT, Ticozzi N, Gellera C, et al. Analysis of the KIFAP3 gene in amyotrophic lateral sclerosis: a multicenter survival study. Neurobiol Aging 2014;35(10):2420e13-24
   Web of Science ®Google Scholar
• Crow JP, Calingasan NY, Chen J, et al. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol 2005;58(2):258-65
   PubMed Web of Science ®Google Scholar
• Matthews RT, Yang L, Browne S, et al. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A 1998;95(15):8892-7
   PubMed Web of Science ®Google Scholar
• Andreassen OA, Jenkins BG, Dedeoglu A, et al. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J Neurochem 2001;77(2):383-90
   PubMed Web of Science ®Google Scholar
• Shefner JM, Cudkowicz ME, Schoenfeld D, et al. A clinical trial of creatine in ALS. Neurology 2004;63(9):1656-61
   PubMed Web of Science ®Google Scholar
• Ito H, Wate R, Zhang J, et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol 2008;213(2):448-55
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cook A, Kim J, et al. Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2013;55:26-35
   PubMed Web of Science ®Google Scholar
• Weishaupt JH, Bartels C, Polking E, et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 2006;41(4):313-23
   PubMed Web of Science ®Google Scholar
• Louwerse ES, Buchet JP, Van Dijk MA, et al. Urinary excretion of lead and mercury after oral administration of meso-2,3-dimercaptosuccinic acid in patients with motor neuron disease. Int Arch Occup Environ Health 1995;67(2):135-8
   PubMed Web of Science ®Google Scholar
• Andreassen OA, Dedeoglu A, Klivenyi P, et al. N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport 2000;11(11):2491-3
   PubMed Web of Science ®Google Scholar
• Bordet T, Buisson B, Michaud M, et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 2007;322(2):709-20
   PubMed Web of Science ®Google Scholar
• Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39(2):147-57
   PubMed Web of Science ®Google Scholar
• Desnuelle C, Dib M, Garrel C, et al. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2(1):9-18
   PubMed Web of Science ®Google Scholar
• Graf M, Ecker D, Horowski R, et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm 2005;112(5):649-60
   PubMed Web of Science ®Google Scholar
• Shoemaker JL, Seely KA, Reed RL, et al. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 2007;101(1):87-98
   PubMed Web of Science ®Google Scholar
• Drachman DB, Frank K, Dykes-Hoberg M, et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 2002;52(6):771-8
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006;60(1):22-31
   PubMed Web of Science ®Google Scholar
• Koh SH, Kim Y, Kim HY, et al. Recombinant human erythropoietin suppresses symptom onset and progression of G93A-SOD1 mouse model of ALS by preventing motor neuron death and inflammation. Eur J Neurosci 2007;25(7):1923-30
   PubMed Web of Science ®Google Scholar
• Lauria G, Campanella A, Filippini G, et al. Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. Amyotroph Lateral Scler 2009;10(5-6):410-15
   PubMed Web of Science ®Google Scholar
• Gordon PH, Doorish C, Montes J, et al. Randomized controlled phase II trial of glatiramer acetate in ALS. Neurology 2006;66(7):1117-19
   PubMed Web of Science ®Google Scholar
• Haenggeli C, Julien JP, Mosley RL, et al. Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS. Neurobiol Dis 2007;26(1):146-52
   PubMed Web of Science ®Google Scholar
• Meininger V, Drory VE, Leigh PN, et al. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial. Amyotroph Lateral Scler 2009;10(5-6):378-83
   PubMed Web of Science ®Google Scholar
• Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002;10(3):268-78
   PubMed Web of Science ®Google Scholar
• Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417(6884):74-8
   PubMed Web of Science ®Google Scholar
• Van Den Bosch L, Tilkin P, Lemmens G, et al. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002;13(8):1067-70
   PubMed Web of Science ®Google Scholar
• Gordon PH, Moore DH, Gelinas DF, et al. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 2004;62(10):1845-7
   PubMed Web of Science ®Google Scholar
• Kunis G, Baruch K, Miller O, et al. Immunization with a myelin-derived antigen activates the brain’s choroid plexus for recruitment of immunoregulatory cells to the CNS and Attenuates disease progression in a mouse model of ALS. J Neurosci 2015;35(16):6381-93
   PubMed Web of Science ®Google Scholar
• Boston-Howes W, Williams EO, Bogush A, et al. Nordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: therapeutic implications for amyotrophic lateral sclerosis. Exp Neurol 2008;213(1):229-37
   PubMed Web of Science ®Google Scholar
• de Paulis T. ONO-2506. Ono. Curr Opin Investig Drugs 2003;4(7):863-7
   PubMedGoogle Scholar
• Sugai F, Yamamoto Y, Miyaguchi K, et al. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur J Neurosci 2004;20(11):3179-83
   PubMed Web of Science ®Google Scholar
• Feng HL, Leng Y, Ma CH, et al. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 2008;155(3):567-72
   PubMed Web of Science ®Google Scholar
• Rouaux C, Panteleeva I, Rene F, et al. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J Neurosci 2007;27(21):5535-45
   PubMed Web of Science ®Google Scholar
• Crochemore C, Virgili M, Bonamassa B, et al. Long-term dietary administration of valproic acid does not affect, while retinoic acid decreases, the lifespan of G93A mice, a model for amyotrophic lateral sclerosis. Muscle Nerve 2009;39(4):548-52
   PubMed Web of Science ®Google Scholar
• Piepers S, Veldink JH, de Jong SW, et al. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann Neurol 2009;66(2):227-34
   PubMed Web of Science ®Google Scholar
• Schutz B, Reimann J, Dumitrescu-Ozimek L, et al. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci 2005;25(34):7805-12
   PubMed Web of Science ®Google Scholar
• Meyer T, Maier A, Borisow N, et al. Thalidomide causes sinus bradycardia in ALS. J Neurol 2008;255(4):587-91
   PubMed Web of Science ®Google Scholar
• Sagot Y, Toni N, Perrelet D, et al. An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motoneuron disease. Br J Pharmacol 2000;131(4):721-8
   PubMed Web of Science ®Google Scholar
• Groeneveld GJ, van Muiswinkel FL, de Leeuw van Weenen J, et al. CGP 3466B has no effect on disease course of (G93A) mSOD1 transgenic mice. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5(4):220-5
   PubMed Web of Science ®Google Scholar
• Pattee GL, Post GR, Gerber RE, et al. Reduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatment. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4(2):90-5
   PubMed Web of Science ®Google Scholar
• Wang H, Larriviere KS, Keller KE, et al. R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS. Amyotroph Lateral Scler 2008;9(1):50-8
   PubMed Web of Science ®Google Scholar
• Meininger V, Asselain B, Guillet P, et al. Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial. Neurology 2006;66(1):88-92
   PubMed Web of Science ®Google Scholar
• Waibel S, Reuter A, Malessa S, et al. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol 2004;251(9):1080-4
   PubMed Web of Science ®Google Scholar
• Li M, Ona VO, Guegan C, et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000;288(5464):335-9
   PubMed Web of Science ®Google Scholar
• Pitzer C, Kruger C, Plaas C, et al. Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis. Brain 2008;131(Pt 12):3335-47
   PubMed Web of Science ®Google Scholar
• Sun W, Funakoshi H, Nakamura T. Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS. J Neurosci 2002;22(15):6537-48
   PubMed Web of Science ®Google Scholar
• Kadoyama K, Funakoshi H, Ohya W, et al. Hepatocyte growth factor (HGF) attenuates gliosis and motoneuronal degeneration in the brainstem motor nuclei of a transgenic mouse model of ALS. Neurosci Res 2007;59(4):446-56
   PubMed Web of Science ®Google Scholar
• Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 1997;49(6):1621-30
   PubMed Web of Science ®Google Scholar
• Sakowski SA, Schuyler AD, Feldman EL. Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009;10(2):63-73
   PubMed Web of Science ®Google Scholar
• Saenger S, Holtmann B, Nilges MR, et al. Functional improvement in mouse models of familial amyotrophic lateral sclerosis by PEGylated insulin-like growth factor I treatment depends on disease severity. Amyotroph Lateral Scler 2012;13(5):418-29
   PubMed Web of Science ®Google Scholar
• Riddoch-Contreras J, Yang SY, Dick JR, et al. Mechano-growth factor, an IGF-I splice variant, rescues motoneurons and improves muscle function in SOD1(G93A) mice. Exp Neurol 2009;215(2):281-9
   PubMed Web of Science ®Google Scholar
• Zheng C, Skold MK, Li J, et al. VEGF reduces astrogliosis and preserves neuromuscular junctions in ALS transgenic mice. Biochem Biophys Res Commun 2007;363(4):989-93
   PubMed Web of Science ®Google Scholar
• Tovar YRLB, Zepeda A, Tapia R. Vascular endothelial growth factor prevents paralysis and motoneuron death in a rat model of excitotoxic spinal cord neurodegeneration. J Neuropathol Exp Neurol 2007;66(10):913-22
   PubMed Web of Science ®Google Scholar
• Zhang X, Chen S, Li L, et al. Folic acid protects motor neurons against the increased homocysteine, inflammation and apoptosis in SOD1 G93A transgenic mice. Neuropharmacology 2008;54(7):1112-19
   PubMed Web of Science ®Google Scholar
• Lee J, Ryu H, Kowall NW. Motor neuronal protection by L-arginine prolongs survival of mutant SOD1 (G93A) ALS mice. Biochem Biophys Res Commun 2009;384(4):524-9
   PubMed Web of Science ®Google Scholar
• Wang R, Zhang D. Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur J Neurosci 2005;22(9):2376-80
   PubMed Web of Science ®Google Scholar
• Joo IS, Hwang DH, Seok JI, et al. Oral administration of memantine prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Clin Neurol 2007;3(4):181-6
   PubMed Web of Science ®Google Scholar
• Ghadge GD, Slusher BS, Bodner A, et al. Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci U S A 2003;100(16):9554-9
   PubMed Web of Science ®Google Scholar
• Gurney ME, Fleck TJ, Himes CS, et al. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 1998;50(1):62-6
   PubMed Web of Science ®Google Scholar
• Paizs M, Tortarolo M, Bendotti C, et al. Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically. Amyotroph Lateral Scler 2011;12(5):340-4
   PubMed Web of Science ®Google Scholar
• Pascuzzi RM, Shefner J, Chappell AS, et al. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010;11(3):266-71
   PubMed Web of Science ®Google Scholar
• Maragakis NJ, Jackson M, Ganel R, et al. Topiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic mice. Neurosci Lett 2003;338(2):107-10
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003;61(4):456-64
   PubMed Web of Science ®Google Scholar
• Kalmar B, Novoselov S, Gray A, et al. Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. J Neurochem 2008;107(2):339-50
   PubMed Web of Science ®Google Scholar
• Kieran D, Kalmar B, Dick JR, et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004;10(4):402-5
   PubMed Web of Science ®Google Scholar
• Tokuda E, Ono S, Ishige K, et al. Ammonium tetrathiomolybdate delays onset, prolongs survival, and slows progression of disease in a mouse model for amyotrophic lateral sclerosis. Exp Neurol 2008;213(1):122-8
   PubMed Web of Science ®Google Scholar
• Ikeda K, Klinkosz B, Greene T, et al. Effects of brain-derived neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Ann Neurol 1995;37(4):505-11
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Ikeda K, Klinkosz B, et al. Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF. Science 1994;265(5175):1107-10
   PubMed Web of Science ®Google Scholar
• Acsadi G, Anguelov RA, Yang H, et al. Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy. Hum Gene Ther 2002;13(9):1047-59
   PubMed Web of Science ®Google Scholar
• Suzuki M, McHugh J, Tork C, et al. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol Ther 2008;16(12):2002-10
   PubMed Web of Science ®Google Scholar
• Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2008;105(6):2052-7
   PubMed Web of Science ®Google Scholar
• Miller RG, Moore DH, Forshew DA, et al. Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design. Neurology 2011;77(10):973-9
   PubMed Web of Science ®Google Scholar
• Morrison KE, Dhariwal S, Hornabrook R, et al. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2013;12(4):339-45
   PubMed Web of Science ®Google Scholar
• Ryu H, Smith K, Camelo SI, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 2005;93(5):1087-98
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Andres PL, Macdonald SA, et al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler 2009;10(2):99-106
   PubMed Web of Science ®Google Scholar
• Petri S, Kiaei M, Kipiani K, et al. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2006;22(1):40-9
   PubMed Web of Science ®Google Scholar